Clorazepate Dipotassium



Clorazepate Dipotassium





(klor az’ e pate)

Apo-Clorazepate (CAN), Tranxene-T-tab

PREGNANCY CATEGORY D

CONTROLLED SUBSTANCE C-IV


Drug Classes

Antiepileptic

Anxiolytic

Benzodiazepine


Therapeutic Actions

Exact mechanisms not understood; benzodiazepines potentiate the effects of GABA, an inhibitory neurotransmitter; anxiolytic effects occur at doses well below those necessary to cause sedation, ataxia.



Indications



  • Management of anxiety disorders or for short-term relief of symptoms of anxiety


  • Symptomatic relief of acute alcohol withdrawal


  • Adjunctive therapy for partial seizures



Available Forms

Tablets—3.75, 7.5, 15 mg


Dosages

Individualize dosage; increase dosage gradually to avoid adverse effects. Drug is available only in oral forms.

Adults



  • Anxiety: Usual dose is 30 mg/day PO in divided doses tid; adjust gradually within the range of 15–60 mg/day; also may be given as a single daily dose at bedtime with a maximum starting dose of 15 mg. For maintenance, give the 22.5-mg PO tablet in a single daily dose as an alternate form for patients stabilized on 7.5 mg PO tid; do not use to initiate therapy.


  • Adjunct to antiepileptic medication: Maximum initial dose is 7.5 mg PO tid. Increase dosage by no more than 7.5 mg every wk, do not exceed 90 mg/day.


  • Acute alcohol withdrawal: Day 1: 30 mg PO initially, then 30–60 mg in divided doses. Day 2: 45–90 mg PO in divided doses. Day 3: 22.5–45 mg PO in divided doses. Day 4: 15–30 mg PO in divided doses. Thereafter, gradually reduce dose to 7.5–15 mg/day PO, and stop as soon as condition is stable.

Pediatric patients

Jul 20, 2016 | Posted by in NURSING | Comments Off on Clorazepate Dipotassium

Full access? Get Clinical Tree

Get Clinical Tree app for offline access